Shine secures $50M in financing

By staff writers

October 8, 2019 -- Medical isotope firm Shine Medical Technologies has secured $50 million in financing with funds managed by Oaktree Capital Management of Los Angeles.

The funds will support Shine's ongoing construction of a new production facility and its commercialization of the diagnostic and therapeutic isotopes molybdenum-99 (Mo-99) and lutetium-177 (Lu-177).

Shine expects construction of the new facility to be completed in 2021 and isotope production to begin in 2022, the company said.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking